Evaluating IBI3005 for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and tolerability of IBI3005 in patients with unresectable, locally advanced, or metastatic solid tumors. It will determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of the drug. Participants must have previously been treated with a third-generation EGFR TKI and experienced disease progression. The study will exclude patients with uncontrolled diseases or certain infections.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects Should have been previously treated with a third-generation EGFR TKI with disease progression. Subjects with positive other driver genes or METex14 mutations are required to undergo targeted therapy and disease progression.

Exclusion Criteria:

Received live vaccines within 4 weeks prior to first administration of the study drug or plan on receiving any live vaccine during the study.Patients are allowed to receive inactivated vaccines.

Uncontrolled diseases including:

* Infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first dose of the study drug（ antiviral medication for hepatitis B and hepatitis C infection that are compliant with the protocol were allowed）;
* Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
* Acute or chronic active hepatitis B (HbsAg positive and/or HbcAb positive with HBV DNA titer ≥ 104 copies/mL or ≥ 2000 IU/mL or higher than lower limit of detection) or C (HCV Ab positive with HCV RNA titer \> 103 copies/mL or higher than lower limit of detection);
* Active COVID-19 infection with obvious symptoms requiring treatment or hospitalization, such as pyrexia, dyspnea, nausea, vomiting, diarrhea, etc.;
* Active tuberculosis infection, or still on anti-tuberculosis therapy or received anti tuberculosis therapy within 1 year prior to first administration of the study drug;
* Active syphilis infection or latent syphilis requiring treatment;
* Symptomatic congestive heart failure Grade II-IV (New York Heart Association \[NYHA\]), symptomatic or uncontrolled arrhythmias, QTc interval \> 480 ms or personal or family history of congenital long/short QT syndrome;
* Hypertension that does not receive standardized therapy or still uncontrollable hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg); Any history of life-threatening hemorrhage, or hemorrhage requiring (including but not limited to gastrointestinal bleeding, hemoptysis, etc) blood transfusion, endoscopy, or surgery, within 3 months prior to the first administration of study drug;

Where it's running

• Shandong Cancer Hospital & Institute
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Yanxi Pu
• Email: yanxi.pu@innoventbio.com
• Phone: 18523197816

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ASP388B given alone or with standard therapies in solid tumors

  This early study tests ASP388B, first given alone or with standard cancer treatments, to see if it is safe and to find workable dose levels for solid tumors.

  Recruiting at 4 sites Phase 1/2 Astellas Pharma Inc · Lake Success, New York and 3 other locations · NCT07730021

• First-in-human test of EMB-15 in adults with advanced or metastatic solid tumors

  This early phase trial tests EMB-15 to see if it is safe and tolerable in adults whose solid tumors have progressed after standard care or have no standard therapy.

  Recruiting Phase 1 Shanghai EpimAb Biotherapeutics Co., Ltd. · Guangzhou, Guangdong · NCT07607054

• BC3195 plus pembrolizumab in advanced solid tumors

  This trial tests whether adding BC3195 to pembrolizumab is safe and shows preliminary activity in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1/2 Biocity Biopharmaceutics Co., Ltd. · Guangzhou, Guangdong · NCT07469774

• YL202 for advanced non‑small cell lung, colorectal, cervical, and other solid tumors

  This trial will try YL202, an antibody‑drug conjugate that targets HER3, in adults with advanced non‑small cell lung, colorectal, cervical, or other metastatic solid tumors who have received one or two prior systemic treatments.

  Recruiting Phase 2 MediLink Therapeutics (Suzhou) Co., Ltd. · Changsha, Hunan · NCT07202364

• YntraDose™ given before chemotherapy for locally advanced, unresectable pancreatic cancer

  This will test whether a one-time, image-guided injection of YntraDose™ (Y-90 radioactive microspheres) into the pancreatic tumor, combined with standard chemotherapy, is safe and can help control locally advanced unresectable pancreatic cancer.

  Recruiting at 2 sites BetaGlue Therapeutics SpA · Roma and 1 other locations · NCT07155850

• MRG007 (ARR-217) treatment for advanced solid tumors

  This trial will test MRG007 (ARR-217), an antibody-drug conjugate that targets CDH17, in adults with unresectable locally advanced or metastatic solid tumors who have exhausted standard therapies.

  Recruiting at 21 sites Phase 1 ArriVent BioPharma, Inc. · Los Angeles, California and 20 other locations · NCT07066657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.